The trajectory of Sildenafil presents a nuanced case for stakeholders in the medicinal sector. While initially a blockbuster success, creating huge profits, the exclusivity lapse and the subsequent arrival of off-brand competitors have considerably affected income. This raises questions about the ongoing viability of related therapeutic development